Question

The true statement among the following is___

• A. The dose of telmisartan should be reduced in renal failure but not in hepatic failure.
• B. The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renalfailure.
• C. The dose of candesartan should be reduced in mild-moderate liver failure but not in renalfailure.
• D. Losartan acts as a thromboxane A2 antagonist and inhibits platelate aggregation

Answer 1

The Correct Option is D

Let's analyze each option to determine the correct statement:

1. The dose of telmisartan should be reduced in renal failure but not in hepatic failure.

   This is incorrect. Telmisartan, an angiotensin II receptor blocker (ARB), does not require dose adjustment in renal impairment. However, caution or adjustment may be needed in hepatic impairment as telmisartan is primarily metabolized in the liver.

2. The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renal failure.

   Irbesartan also belongs to the ARB class and generally, no specific dose adjustment is required in renal failure. In mild to moderate hepatic impairment, dose adjustment is typically not currently recommended.

3. The dose of candesartan should be reduced in mild-moderate liver failure but not in renal failure.

   Candesartan is another ARB. For patients with moderate hepatic impairment, a lower starting dose may be considered. However, cautious dose adjustments are also necessary in renal impairment, especially severe renal failure.

4. Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation.

   This statement is correct. Losartan is known to antagonize thromboxane A2 receptors, which contributes to its ability to inhibit platelet aggregation aside from its primary function of blocking angiotensin II receptors.